Clinical Trials Directory

Trials / Completed

CompletedNCT05096988

Evaluation of PKU Sphere Liquid

A Study to Evaluate the Acceptability, Tolerance and Adherence of Children and Adults Consuming PKU Sphere Liquid, a Food for Special Medical Purposes (FSMP), for the Dietary Management of Phenylketonuria (PKU)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Vitaflo International, Ltd · Industry
Sex
All
Age
3 Years
Healthy volunteers
Not accepted

Summary

PKU Sphere Liquid is a prospective, open-label, acceptability study to evaluate PKU sphere liquid in up to 15 participants aged 3 and above for the dietary management of PKU over 31 days.

Detailed description

PKU Sphere Liquid is a newly-developed Food for Special Medical Purposes (FSMP) designed for the dietary management of patients with phenylketonuria (PKU). PKU sphere liquid is a vanilla flavoured, ready-to-drink, low phenylalanine protein substitute containing a blend of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and Docosachexaenoic acid (DHA). This is a feasibility study designed to evaluate the acceptability, tolerance and adherence of children and adults consuming PKU sphere liquid. Participants will be given a four-week supply of PKU Sphere Liquid and they will be asked to complete a daily diary and short questionnaire for four weeks to record information on: adherence, gastrointestinal tolerance, palatability and how the product is used. Each participant will be on the trial for 31 days. This includes a 3-day baseline period and 28 days taking the study product. If deemed appropriate in each individual circumstance, the sponsor of the trial, Vitaflo International Ltd, will continue to supply the product free of charge at the end of the trial until available on prescription.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPKU sphere liquidPKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.

Timeline

Start date
2021-11-23
Primary completion
2022-06-21
Completion
2023-02-28
First posted
2021-10-27
Last updated
2024-02-16

Locations

3 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05096988. Inclusion in this directory is not an endorsement.